Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06906367 · ClinicalTrials.gov registry record

A Study of Patients With Fabry Disease (US Specific)

A clinical trial of Fabry Disease, sponsored by Amicus Therapeutics.

Recruiting
Registry status
450
Enrollment target
7
Study locations

NCT06906367 is a study of Fabry Disease that is actively recruiting participants, run by Amicus Therapeutics. The registered enrollment target is 450 participants, below the 529-participant average among 32 other Fabry Disease trials with a reported enrollment target (15% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06906367, a study of Fabry Disease, is actively recruiting participants, sponsored by Amicus Therapeutics.

RECRUITING
Registry status
450 participants
Enrollment target
7
Study locations

Study Summary

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

Conditions Studied

Fabry Disease

Interventions

  • DRUG migalastat HCl
  • DRUG ERT

Study Locations (7)

Alabama

  • UAB Nephrology Research Clinic at Paula Building - Birmingham

Arkansas

  • Arkansas Children's Hospital - Little Rock

Georgia

  • Emory Genetics - Atlanta

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • UPMC Children's Hospital of Pittsburgh - Pittsburgh

Texas

  • Renal Disease Research Institute - Dallas

Virginia

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc. - Fairfax

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2026-02-13
Est. Completion 2032-06

Sponsor

Amicus Therapeutics

34 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06906367

The ClinicalTrials.gov registry entry for NCT06906367 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 529-participant average among 32 other Fabry Disease trials with a reported enrollment target (15% lower). The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 2 interventions - of which migalastat HCl is the first listed.

NCT06906367 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Alabama, Arkansas, Georgia.

Frequently Asked Questions

What is clinical trial NCT06906367 about?

NCT06906367 is a clinical study titled "A Study of Patients With Fabry Disease (US Specific)". This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

What is the current status of trial NCT06906367?

This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2026-02-13. Estimated completion is 2032-06.

What conditions does trial NCT06906367 study?

This clinical trial studies the following conditions: Fabry Disease.

What interventions are being tested in trial NCT06906367?

The interventions under investigation include: migalastat HCl (DRUG), ERT (DRUG).

Who is sponsoring clinical trial NCT06906367?

This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06906367 being conducted?

This trial has 7 study locations across Alabama, Arkansas, Georgia, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fabry Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fabry Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.